{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:44:47Z","timestamp":1785465887569,"version":"3.56.0"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:p>Programmed death-ligand 1 (PD-L1\/CD274) structural variation (SV) disrupting the 3\u2032-untranslated region has been highlighted as being associated with PD-L1 overexpression. In the present study, we evaluated lymphoma tissue samples to investigate the applicability of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) for detecting the PD-L1 SV involving the 3\u2032-untranslated region. In total, 1052 lymphoma samples were screened using IHC, and 99 IHC screening-positive samples were evaluated with FISH (non-Hodgkin lymphoma [NHL, n=58] and Hodgkin lymphoma [HL, n=41]). Of these, 92 samples showed strong PD-L1 expression with 2 PD-L1 antibodies (E1J2J and SP142) (concordant PD-L1 IHC), whereas 7 samples showed strong PD-L1 expression only with E1J2J (discordant PD-L1 IHC). Abnormal FISH findings for PD-L1 were detected in all evaluated samples (51 NHLs and 41 HLs). A structural abnormality pattern was observed in 17 of the 51 evaluated NHL samples (33%). In contrast, all 41 HL samples showed a copy number abnormality pattern, with 1 exhibiting a structural abnormality pattern. Target-capture sequencing of the PD-L1 gene was performed on 73 of the 99 IHC screening-positive samples, comprising 41 NHLs and 32 HLs. PD-L1 SVs were detected in 16 (39%) of the 41 NHL samples and in only one of the 32 HL samples (3%). Samples exhibiting discordant PD-L1 IHC and\/or FISH structural abnormality patterns were shown to harbor PD-L1 SV by target-capture sequencing, with positive and negative predictive values of 94% and 96%, respectively. Our approach is an alternative to target-capture sequencing for evaluating PD-L1 gene abnormalities.<\/jats:p>","DOI":"10.1097\/pas.0000000000002372","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T11:00:16Z","timestamp":1740999616000},"page":"490-498","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["High-accuracy Detection of PD-L1 3\u2019-UTR Disruption by Immunohistochemistry and Fluorescence in Situ Hybridization on Formalin-fixed Paraffin-embedded Sections"],"prefix":"10.1097","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5406-9300","authenticated-orcid":false,"given":"Ayumi","family":"Fujimoto","sequence":"first","affiliation":[{"name":"Pathology Project for Molecular Targets, Cancer Institute"},{"name":"Division of Pathology, Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Sakata","sequence":"additional","affiliation":[{"name":"Pathology Project for Molecular Targets, Cancer Institute"},{"name":"Division of Pathology, Cancer Institute"},{"name":"Department of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Kataoka","sequence":"additional","affiliation":[{"name":"Division of Molecular Oncology, National Cancer Center Research Institute"},{"name":"Division of Hematology, Department of Medicine, Keio University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Kogure","sequence":"additional","affiliation":[{"name":"Division of Molecular Oncology, National Cancer Center Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Chiba","sequence":"additional","affiliation":[{"name":"Division of Genome Analysis Platform Development, National Cancer Center Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Okada","sequence":"additional","affiliation":[{"name":"Division of Genome Analysis Platform Development, National Cancer Center Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Shiraishi","sequence":"additional","affiliation":[{"name":"Division of Genome Analysis Platform Development, National Cancer Center Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Baba","sequence":"additional","affiliation":[{"name":"Pathology Project for Molecular Targets, Cancer Institute"},{"name":"Division of Pathology, Cancer Institute"},{"name":"Department of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seishi","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1599-5800","authenticated-orcid":false,"given":"Kengo","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Pathology Project for Molecular Targets, Cancer Institute"},{"name":"Division of Pathology, Cancer Institute"},{"name":"Department of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"R1-20250416","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 expression as a predictive biomarker in cancer immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"R2-20250416","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"R3-20250416","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"R4-20250416","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13045-020-01027-5","article-title":"Regulation of PD-L1 expression in the tumor microenvironment","volume":"14","author":"Yi","year":"2021","journal-title":"J Hematol Oncol"},{"key":"R5-20250416","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep"},{"key":"R6-20250416","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"R7-20250416","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"R8-20250416","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature18294","article-title":"Aberrant PD-L1 expression through 3\u2019-UTR disruption in multiple cancers","volume":"534","author":"Kataoka","year":"2016","journal-title":"Nature"},{"key":"R9-20250416","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.3390\/genes14081620","article-title":"The 3\u2019 non-coding sequence negatively regulates PD-L1 expression, and its regulators are systematically identified in pan-cancer","volume":"14","author":"Chen","year":"2023","journal-title":"Genes"},{"key":"R10-20250416","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1038\/s41375-019-0380-5","article-title":"Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas","volume":"33","author":"Kataoka","year":"2019","journal-title":"Leukemia"},{"key":"R11-20250416","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood-2016-12-754796","article-title":"Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation","volume":"129","author":"Yoshizato","year":"2017","journal-title":"Blood"},{"key":"R12-20250416","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"key":"R13-20250416","doi-asserted-by":"crossref","first-page":"e0166266","DOI":"10.1371\/journal.pone.0166266","article-title":"PD-L1 status in refractory lymphomas","volume":"11","author":"Vranic","year":"2016","journal-title":"PLoS One"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002372","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T14:00:47Z","timestamp":1744812047000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000002372","relation":{},"ISSN":["0147-5185","1532-0979"],"issn-type":[{"value":"0147-5185","type":"print"},{"value":"1532-0979","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]}}}